RNAi is a fundamental gene-silencing pathway in eukaryotic cells, where long pieces of double-stranded RNA are cleaved by an enzyme called dicer into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute.Currently, the RNA interference domain constitutes an immensely robust pipeline with more than 90+ drugs under different phases of development. RNA molecules are extremely diverse, with a plethora of functions in the cell. RNA was actually underpinned as the essential molecule in the origin of life; its structural, enzymatic, and encoding functions recapitulate the key features of life.DelveInsight brings into focus RNA interference therapeutics applications, RNA types and biology, and challenges in siRNA delivery. Additionally, RNA interference research and developmental activities, pipeline assessment, and key RNAi companies are thoroughly covered in this newsletter. Learn more about the recent happenings, ongoing research &amp; development, significant pharmaceutical companies involved in the RNA interference market, top-notch collaborations anticipated to occur, licensing &amp; fundings, and breakthroughs in the RNA interference market landscape.Get a sneak peek of the RNA interference pipeline therapies, clinical trials, deals &amp; tie-ups, and upcoming world-class conferences, as well as track all the recent updates in the RNA interference market.&nbsp;Interested in knowing more about what upcoming years hold for the RNA interference market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form on the right.Stay tuned!

RNAi is a fundamental gene-silencing pathway in eukaryotic cells, where long pieces of double-stranded RNA are cleaved by an enzyme called dicer into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute.

RNA Interference

RNA interference research and developmental activities, pipeline assessment, and key RNAi companies are thoroughly covered in this newsletter